flavin-mononucleotide has been researched along with Chronic-Disease* in 12 studies
1 review(s) available for flavin-mononucleotide and Chronic-Disease
Article | Year |
---|---|
[Pathogenetic correction of metabolic disturbances in chronic liver affections].
The available drugs for the treatment of chronic liver affections (the adequate model is chronic hepatitis C) include agents of metabolic therapy, whose efficacy is not always enough, that required the search for original mitochondrial substrates on the basis of succinate. Such agents were composed as a pharmaceutical group named "Substrates of Energetic Metabolism" or "Substrate Antihypoxants". The review presents the description of the pharmacological effects of remaxole and cytoflavin, evident from lower levels of active metabolites of oxygen that increases the clinical efficacy of the therapy. Their role in the metabolic reactions in chronic liver affections is exclusive and rather actual. Topics: Apoptosis; Chronic Disease; Drug Combinations; Flavin Mononucleotide; Glutathione Disulfide; Hepatitis C, Chronic; Humans; Inosine Diphosphate; Lipid Peroxidation; Liver Diseases; Niacinamide; Protective Agents; Succinates | 2012 |
7 trial(s) available for flavin-mononucleotide and Chronic-Disease
Article | Year |
---|---|
[THE INFLUENCE OF CYTOFLAVIN AND CARDIOXIPIN ON THE PARAMETERS OF 24-HOUR ARTERIAL PRESSURE MONITORING IN PATIENTS WITH CHRONIC CEREBRAL CIRCULATION INSUFFICIENCY, ARTERIAL HYPERTENSION AND HYPERCHOLESTEROLEMIA].
This comparative study of the influence of cytoflavin and cardioxipin on the parameters of 24-hour arterial pressure monitoring in 56 patients with chronic cerebral circulation insufficiency, arterial hypertension and hypercholesterolemia included 32 women and 24 men aged 42-72 years divided into 3 groups matchedfor the stage of diseases, age, sex, severity of AH, total cholesterol level, and antihypertensive therapy. Patients of group 1 were treated without cytoflavin and cardioxipin. Those in group 2 received daily i/v droplet infusion of 10 mg/kg cardioxipin (20-30 droplets/min). Patients of group 3 were given daily i/v droplet infusion of 10 ml cytoflavin in 200 ml 0.9% sodium chloride solution for 10 days. 24-hour arterial pressure monitoring was used to estimate the influence of the two drugs on systolic and diastolic pressure, its daily rhythm, AP variability and frequency of elevation. The study showed that both therapeutic modalities improved daily AP rhythm as manifested in a significant increase of the number of patients with the dipper rhythm and a decrease in the number of systolic/diastolic non-dipper patients. Moreover cytoflavin significantly decreased the number of systolic over-dippers compared with control group. Topics: Adult; Aged; Antihypertensive Agents; Arterial Pressure; Blood Pressure Monitoring, Ambulatory; Cerebrovascular Circulation; Cerebrovascular Disorders; Chronic Disease; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Female; Flavin Mononucleotide; Follow-Up Studies; Humans; Hypercholesterolemia; Hypertension; Infusions, Intravenous; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Retrospective Studies; Succinates; Treatment Outcome | 2015 |
[An effect of cytoprotective therapy on stress resistance and compensatory abilities of patients with chronic cerebral ischemia].
To study an effect of nonspecific cytoprotective therapy on clinical manifestations, disease course and indicators of stress system in patients with different stages of chronic cerebral ischemia (CCI).. Authors examined 266 patients with CCI, aged from 35 to 55 years. The patients received basic and nonspecific cytoprotective therapy. The dynamics of subjective and objective symptoms of encephalopathy, clinical outcomes after a year of observation, and the state of stress system were analyzed. An effect of therapy on stress was assessed by the dynamics of blood pressure reactions to stress.. An open randomized comparative study has shown that the inclusion of the drug with nonspecific cytoprotective actions (cytoflavin) in the therapeutic complex improves the therapeutic effect on the clinical manifestations of CCI. The higher frequency of favorable outcomes over one year of follow-up is associated with the optimization of stress system activity under nonspecific cytoprotective therapy and the increase in stress resistance.. Цель исследования - изучить влияние неспецифической цитопротективной терапии на клинические проявления, характер течения заболевания и показатели стрессовой системы у пациентов с разными стадиями хронической ишемии головного мозга (ХИМ). Материал и методы. Обследованы 266 пациентов с ХИМ в возрасте от 35 до 55 лет, получавших базисную и неспецифическую цитопротективную терапию. Была проанализирована динамика субъективных и объективных симптомов ХИМ, клинические исходы через 1 год наблюдения и состояние стрессовой системы. Влияние терапии на стрессоустойчивость оценивали по динамике стрессовых реакций крови. Результаты и заключение. В результате открытого, сравнительного рандомизированного исследования показано, что включение в терапевтический комплекс препарата неспецифического цитопротективного действия (цитофлавин) повышает эффективность воздействия на клинические проявления ХИМ. Повышение числа благоприятных исходов через 1 год наблюдения было ассоциировано с оптимизацией деятельности стрессовой системы при применении неспецифической цитопротективной терапии и повышением стрессоустойчивости. Topics: Adult; Antioxidants; Brain Ischemia; Chronic Disease; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Neuroprotective Agents; Niacinamide; Stress, Physiological; Succinates; Treatment Outcome | 2015 |
[Dynamics of the symptoms of chronic ischemia during the treatment with cytoflavin].
Sixty patients with chronic brain ischemia (discirculatory encephalopathy, I and II stages) were enrolled in the study. Patients of the first group (n=30) were treated with cytoflavin and patients of the second group (n=30) received piracetam prescribed first as injections and then in pills. The treatment duration was 35 days. Standard neurological examination and psychometric assessment of patients and dopplerography of cerebral vessels were carried out. Cytoflavin was shown to have a positive effect on the neurological status. It decreases asthenic, cephalgia and vestibulo-cerebellar syndromes as well as neurological and emotional disturbances reducing the symptoms of depression and anxiety and improving cognitive functions and memory as well as quality of life of patients. The changes were significant compared to those in the group of patients treated with piracetam. Topics: Brain; Brain Ischemia; Chronic Disease; Drug Combinations; Female; Flavin Mononucleotide; Hemodynamics; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Psychiatric Status Rating Scales; Regional Blood Flow; Succinates; Treatment Outcome | 2012 |
[Oxidative stress and combined antioxidant energy correction in the treatment of periodontitis].
Experimental-clinical study with inclusion of 50 Wistar rats with modeled parodontitis and 71 patients with chronic generalized parodontitis of different severity degree was conducted. Significance of oxidation stress in disease development and running was established in the course of the study. Disbalance of free-radical processes (FRP) in case of periodontal diseases affects oxygen stage of the oxidation stress in bigger degree and continues for a long time. In the course of experiment positive influence of cytoflavine preparation as energy-correction and antioxidant was confirmed as well as its combination with calcium-D3. In the course of comprehensive clinical study the efficacy of cytoflavine use was verified by the example of FRP correction that was accompanied by clinical picture and treatment results improvement. Topics: Adult; Aged; Animals; Antioxidants; Calcium; Cholecalciferol; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Energy Metabolism; Female; Flavin Mononucleotide; Free Radicals; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Oxidative Stress; Periodontitis; Rats; Rats, Wistar; Succinates | 2011 |
[The use of cytoflavin for the treatment of chronic brucellosis].
Clinical and pathogenetic efficacy of cytoflavin as a component of combined therapy of chronic brucellosis was tested in 50 patients who repeated its beneficial effect on the quality of life. The mechanism of cytoflavin action consists of lowering severity of endogenous intoxication and systemic inflammation. Topics: Adult; Brucellosis; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide; Succinates; Treatment Outcome | 2011 |
[Pharmacotherapy of basic clinical presentations of chronic brain ischemia].
Topics: Antioxidants; Brain Ischemia; Chronic Disease; Drug Combinations; Flavin Mononucleotide; Humans; Inosine Diphosphate; Neuroprotective Agents; Niacinamide; Succinates | 2011 |
[Improvement of speech discrimination with cytoflavin in patients with chronic sensorineural deafness].
Topics: Aged; Chronic Disease; Drug Combinations; Female; Flavin Mononucleotide; Hearing Loss, Sensorineural; Humans; Inosine Diphosphate; Male; Middle Aged; Neuroprotective Agents; Niacinamide; Speech Perception; Succinates; Treatment Outcome | 2010 |
4 other study(ies) available for flavin-mononucleotide and Chronic-Disease
Article | Year |
---|---|
[STRESS-PROTECTIVE EFFECT OF CYTOFLAVIN ON CHRONIC CEREBRAL ISCHEMIA IN RATS.]
Analysis of stress-releasing blood reactions (electrophoretic mobility of red blood cells, WBC count, and leukocyte ratio) in rats with experimental cerebral ischernia under the action of cytoflavin held showed that cytoflavin in combination with basic therapy leads to further activation of compensatory-adaptive reactions of the body and stimulated peripheral stress-limiting mechanisms. Topics: Animals; Brain Ischemia; Chronic Disease; Drug Combinations; Erythrocytes; Flavin Mononucleotide; Inosine Diphosphate; Leukocyte Count; Male; Niacinamide; Rats; Rats, Wistar; Succinates | 2016 |
[The diagnostics of adaptive reactions of blood on application the stress-modulating therapy in patients with brain chronic ischemia].
The article deals with the results of analysis of electrophoretic mobility of erythrocytes and leukogram in patients with dyscirculatory encephalopathy on different stages of disease on application therapy with inclusion of stress-modulating pharmaceuticals into course of treatment. It is established that the electrophoretic mobiliy of erythrocytes makes it possible to evaluate the adaptive indicators blood in patients with dyscirculatory encephalopathy. The consideration of these indicators makes feasible the substantiation of inclusion of stress-modulating therapy into complex treatment of patients with chronic cerebrovascular inefficiency. Topics: Adult; Brain Ischemia; Chronic Disease; Delta Sleep-Inducing Peptide; Drug Combinations; Erythrocytes; Flavin Mononucleotide; Glycine; Humans; Inosine Diphosphate; Middle Aged; Niacinamide; Succinates | 2012 |
[Antioxidant and membranoprotector treatment of chronic pyelonephritis].
The results of investigation of the clinical efficiency of using the antioxidant drug cytoflavin in a complex therapy of patients with chronic pyelonephritis prior to development of azotemia are presented. It is shown that cytoflavin in combination with basic therapy reduces the intensity of lipid peroxidation processes (as monitored using diene conjugates, malonic dialdehyde, and Schiffbase metabolites) with retention of the antioxidant status. The proposed treatment normalizes the ratio of blood plasma phospholipid fractions and erythrocytes membranes. Topics: Adult; Antioxidants; Azotemia; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Erythrocyte Membrane; Erythrocytes; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Lipid Peroxidation; Lipid Peroxides; Male; Middle Aged; Niacinamide; Phospholipids; Pyelonephritis; Succinates | 2011 |
[Efficacy of cytoflavin in the treatment of chronic cerebral ischemia].
The author presents results of multicentre randomized studies of therapeutic efficiency of cytoflavin tablets in patients with chronic cerebral ischemia including asthenovegetative syndrome. Cytoflavin was shown to reduce clinical manifestations of asthenia, anxiety, depression, cognitive and emotional disorders and simultaneously improve quality of life. The efficiency of cytoflavin is confirmed by improved physical and psychic state of the patients, their enhanced social activity. Topics: Asthenia; Brain Ischemia; Chronic Disease; Drug Combinations; Flavin Mononucleotide; Humans; Inosine Diphosphate; Multicenter Studies as Topic; Neuropsychological Tests; Niacinamide; Quality of Life; Randomized Controlled Trials as Topic; Succinates | 2010 |